1‑MNA is a discovery resulting from many years of research carried out by scientists in various research centres all over the world. The molecule is patented (EP 1713480). 1-MNA is a physiological substance of vitamin origin, found also in nature. Clinical trials reveal that with age our physiological ability to synthesize 1‑MNA gradually decreases, therefore 1‑MNA supplementation is especially recommended for the elderly.
In May 2013, PHARMENA began its efforts aimed at marketing an innovative dietary supplement based on 1‑MNA. The company applied to the Food Standards Agency (FSA) in London for the authorization of 1-MNA as a novel food ingredient pursuant to Article 4 of the Regulation No. 258/97.
In August 2018, the European Commission authorized 1‑MNA as a novel food ingredient and additionally granted the Issuer a five‑year protection of the scientific data contained in the 1‑MNA authorization application, which means an exclusive right to market novel food containing 1‑MNA for the period of five years from the date of issuing a marketing authorization for the novel food.
PHARMENA plans to build in Poland a strong brand named ENDOTELIO for dietary supplements based on the innovative 1‑MNA molecule. The Company plans to grow its portfolio further by marketing new innovative products.
PHARMENA also plans to develop the ENDOTELIO dietary supplement brand globally, launching it for sale in Europe and the United States of America